Generic Drug Probes, SEC Committee, HSBC Hire: Compliance

U.S. regulators, armed with a year-old Supreme Court decision, are stepping up investigations of pharmaceutical deals that delay the sale of generic drugs, arrangements they view as illegally hurting competition.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.